123 related articles for article (PubMed ID: 1325886)
21. Neutral endopeptidase inhibition attenuates development of hypoxic pulmonary hypertension in rats.
Klinger JR; Petit RD; Warburton RR; Wrenn DS; Arnal F; Hill NS
J Appl Physiol (1985); 1993 Oct; 75(4):1615-23. PubMed ID: 8282611
[TBL] [Abstract][Full Text] [Related]
22. Heart failure augments the cardiovascular and renal effects of neutral endopeptidase inhibition in rats.
Trippodo NC; Gabel RA; Harvey CM; Asaad MM; Rogers WL
J Cardiovasc Pharmacol; 1991 Sep; 18(3):308-16. PubMed ID: 1720829
[TBL] [Abstract][Full Text] [Related]
23. Cardiorenal actions of neutral endopeptidase inhibition in experimental congestive heart failure.
Cavero PG; Margulies KB; Winaver J; Seymour AA; Delaney NG; Burnett JC
Circulation; 1990 Jul; 82(1):196-201. PubMed ID: 2142023
[TBL] [Abstract][Full Text] [Related]
24. Neutral endopeptidase 24.11 inhibition may not exhibit beneficial haemodynamic effects in patients with congestive heart failure.
Kentsch M; Otter W; Drummer C; Nötges A; Gerzer R; Müller-Esch G
Eur J Clin Pharmacol; 1996; 51(3-4):269-72. PubMed ID: 9010697
[TBL] [Abstract][Full Text] [Related]
25. Role of neutral endopeptidase 24.11 in AV fistular rat model of heart failure.
Wegner M; Hirth-Dietrich C; Stasch JP
Cardiovasc Res; 1996 Jun; 31(6):891-8. PubMed ID: 8759244
[TBL] [Abstract][Full Text] [Related]
26. Glucocorticoids improve renal responsiveness to atrial natriuretic peptide by up-regulating natriuretic peptide receptor-A expression in the renal inner medullary collecting duct in decompensated heart failure.
Liu C; Chen Y; Kang Y; Ni Z; Xiu H; Guan J; Liu K
J Pharmacol Exp Ther; 2011 Oct; 339(1):203-9. PubMed ID: 21737535
[TBL] [Abstract][Full Text] [Related]
27. Atrial natriuretic peptide in congestive heart failure in the dog: plasma levels, cyclic guanosine monophosphate, ultrastructure of atrial myoendocrine cells, and hemodynamic, hormonal, and renal effects.
Riegger GA; Elsner D; Kromer EP; Daffner C; Forssmann WG; Muders F; Pascher EW; Kochsiek K
Circulation; 1988 Feb; 77(2):398-406. PubMed ID: 2962788
[TBL] [Abstract][Full Text] [Related]
28. Atrial natriuretic factor-potentiating and antihypertensive activity of SCH 34826. An orally active neutral metalloendopeptidase inhibitor.
Sybertz EJ; Chiu PJ; Vemulapalli S; Watkins R; Haslanger MF
Hypertension; 1990 Feb; 15(2):152-61. PubMed ID: 2154404
[TBL] [Abstract][Full Text] [Related]
29. Hemodynamic, renal, and hormonal effects of 8-Br-cyclic GMP in conscious dogs with and without congestive heart failure.
Elsner D; Kromer EP; Riegger GA
J Cardiovasc Pharmacol; 1989 Aug; 14(2):241-7. PubMed ID: 2476597
[TBL] [Abstract][Full Text] [Related]
30. Effects of neutral endopeptidase inhibition in the rat remnant kidney model.
Jandeleit-Dahm K; Burrell LM; Kanazawa M; Casley D; Jackson B; Johnston CI
Kidney Blood Press Res; 1998; 21(6):419-24. PubMed ID: 9933826
[TBL] [Abstract][Full Text] [Related]
31. The neutral endopeptidase inhibitor, SCH 34826, reduces left ventricular hypertrophy in spontaneously hypertensive rats.
Monopoli A; Ongini E; Cigola E; Olivetti G
J Cardiovasc Pharmacol; 1992 Sep; 20(3):496-504. PubMed ID: 1279298
[TBL] [Abstract][Full Text] [Related]
32. Hemodynamic and humoral effects of chronic treatment with the neutral endopeptidase inhibitor SCH 42495 in spontaneously hypertensive rats.
Sala C; Monopoli A; Casati C; Ardeleani G; Ongini E; Zanchetti A; Morganti A
J Cardiovasc Pharmacol; 1994 May; 23(5):703-8. PubMed ID: 7521451
[TBL] [Abstract][Full Text] [Related]
33. Beneficial renal and cardiac effects of vasopeptidase inhibition with S21402 in heart failure.
Burrell LM; Farina NK; Balding LC; Johnston CI
Hypertension; 2000 Dec; 36(6):1105-11. PubMed ID: 11116133
[TBL] [Abstract][Full Text] [Related]
34. Maximizing the natriuretic peptide system in experimental heart failure: subcutaneous brain natriuretic peptide and acute vasopeptidase inhibition.
Chen HH; Lainchbury JG; Harty GJ; Burnett JC
Circulation; 2002 Feb; 105(8):999-1003. PubMed ID: 11864932
[TBL] [Abstract][Full Text] [Related]
35. Intrarenal effects of ecadotril during acute volume expansion in dogs with congestive heart failure.
Solter P; Sisson D; Thomas W; Goetze L
J Pharmacol Exp Ther; 2000 Jun; 293(3):989-95. PubMed ID: 10869402
[TBL] [Abstract][Full Text] [Related]
36. Excretory responses to renal nerve stimulation during inhibition of neutral metalloendopeptidase and angiotensin-converting enzyme in the rat.
Golin R; Protasoni G; Wjinmaalen P; Sala C; Monopoli A; Casati C; Zanchetti A; Stella A
J Cardiovasc Pharmacol; 1996 Nov; 28(5):665-71. PubMed ID: 8945680
[TBL] [Abstract][Full Text] [Related]
37. Antihypertensive and renal activity of SQ 28,603, an inhibitor of neutral endopeptidase.
Seymour AA; Norman JA; Asaad MM; Fennell SA; Little DK; Kratunis VJ; Rogers WL
J Cardiovasc Pharmacol; 1991 Feb; 17(2):296-304. PubMed ID: 1709235
[TBL] [Abstract][Full Text] [Related]
38. BNP: pathophysiological and potential therapeutic roles in acute congestive heart failure.
Grantham JA; Borgeson DD; Burnett JC
Am J Physiol; 1997 Apr; 272(4 Pt 2):R1077-83. PubMed ID: 9140004
[TBL] [Abstract][Full Text] [Related]
39. The blood pressure and renal responses to SCH 34826, a neutral metalloendopeptidase inhibitor, and C-ANF (4-23) in Doca-salt hypertensive rats.
Vemulapalli S; Chiu PJ; Brown A; Griscti K; Sybertz EJ
Life Sci; 1991; 49(5):383-91. PubMed ID: 1649942
[TBL] [Abstract][Full Text] [Related]
40. Differential actions of vasopeptidase inhibition versus angiotensin-converting enzyme inhibition on diuretic therapy in experimental congestive heart failure.
Cataliotti A; Boerrigter G; Chen HH; Jougasaki M; Costello LC; Tsuruda T; Lee SC; Malatino LS; Burnett JC
Circulation; 2002 Feb; 105(5):639-44. PubMed ID: 11827932
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
